Faldaprevir is a first-generation HCV protease inhibitor that has been extensively studied; TD-6450 is an HCV NS5A inhibitor that is an experimental drug. The study is evaluating the safety and effectiveness of the two drugs taken with and without ribavirin. The study is accepting treatment naïve patients (with exceptions – see complete study description).
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
To read the entire clinical trial description, click here…
Share This Page